Cathelicidin

Family Overview

Cathelicidins are a widely conserved family of vertebrate antimicrobial peptides defined not by sequence but by architecture: each member is translated as a precursor containing a highly conserved N-terminal cathelin domain (about 100 residues, homologous to cathepsin L inhibitors) followed by a variable C-terminal antimicrobial peptide that is released by proteolytic cleavage when the precursor is deployed. Humans have a single cathelicidin gene (CAMP), which encodes the precursor protein hCAP18; its mature antimicrobial fragment is LL-37. Other mammals carry many more — cattle have at least 11 cathelicidins, and pigs have the well-studied PR-39 and protegrins.

This family-level diversity matters clinically: research and veterinary work on cathelicidins frequently draws on non-human orthologues (bovine indolicidin, porcine PR-39, mouse CRAMP), and readers encountering "cathelicidin" in the literature should always check which species-specific peptide is meant.

Mechanism of Action

Cathelicidin peptides share several core activities despite their sequence diversity:

• Membrane permeabilization. Most mature cathelicidins are cationic and amphipathic; they bind anionic microbial membranes and disrupt bilayer integrity at micromolar concentrations.
• Chemotaxis and immune signaling. Human LL-37 and several animal cathelicidins recruit neutrophils, monocytes, and T-cells through formyl peptide receptor 2 (FPR2) and other receptors, acting as bridges between innate antimicrobial defense and adaptive immune mobilization.
• Wound-healing and angiogenic effects. Cathelicidins upregulate VEGF, stimulate keratinocyte migration, and accelerate re-epithelialization — activities independent of their antimicrobial function.
• LPS neutralization. Binding of endotoxin reduces TLR4-mediated inflammation in vitro and in sepsis models.

Cathelicidin expression is inducible by vitamin D signaling — the CAMP promoter contains a vitamin D response element — which accounts for the observed correlations between vitamin D status, infection susceptibility, and wound healing.

Disease Associations and Research Context

Cathelicidin biology intersects with several clinical phenotypes:

• Rosacea. Facial skin in rosacea shows abnormally high cathelicidin expression and aberrant proteolytic processing, producing LL-37 variants that drive inflammation — an important mechanistic insight that links innate immunity to a common dermatologic disease.
• Atopic dermatitis. Atopic skin shows impaired cathelicidin induction, contributing to Staphylococcus aureus colonization.
• Tuberculosis. Vitamin D–driven cathelicidin induction in macrophages is part of the innate response to intracellular Mycobacterium tuberculosis, a mechanism that has re-anchored interest in vitamin D as an adjunct in TB management.
• Cystic fibrosis. Like other cationic antimicrobial peptides, cathelicidins lose activity in the high-salt airway surface liquid characteristic of CF.

Clinical Development

Therapeutic development in this space has focused on species-specific mature peptides (primarily LL-37 and its truncated analogues) rather than the intact precursor. Several biotech programs have pursued cathelicidin-based topical antimicrobials, wound-healing agents, and anti-biofilm compounds. None has achieved major regulatory approval as of early 2026. For detailed clinical and dosing information on the human mature peptide, see the dedicated LL-37 reference page.

Practical Considerations

For the purposes of a research or clinical user, "cathelicidin" is rarely what is being administered — the relevant therapeutic or research molecule is almost always a specific mature peptide such as LL-37, a truncated variant (IG-25, KR-12), or a veterinary cathelicidin used in specific research contexts. Any commercial product labelled simply "cathelicidin" should be scrutinized for which peptide it actually contains.

Regulatory and Safety Status

No cathelicidin-class peptide is FDA- or EMA-approved as a human therapeutic in 2026. The class is active in preclinical and early-clinical development, and indirect modulation through vitamin D optimization is the most accessible way to influence endogenous cathelicidin levels. Safety profiles vary considerably across the family — some cathelicidins show significant cytotoxicity against mammalian cells at concentrations close to their antimicrobial thresholds, which has complicated systemic drug development.

The Bottom Line

Cathelicidins are a central family in vertebrate innate immunity and a rich source of candidate antimicrobial and wound-healing peptides, but as a therapeutic class they remain mostly promise rather than product. The human member LL-37 is the one most likely to be relevant to readers, and the closely related beta-defensin-2 and lactoferrin peptides together form the core of the human antimicrobial peptide toolkit.